DRUG CHARACTERISTICS ASSOCIATED WITH GENERIC UPTAKE AFTER LOSS OF MARKET EXCLUSIVITY

被引：0
|
作者：
Rome, Benjamin N. [1 ,2 ]
Lee, ChangWon C. [1 ]
Kesselheim, Aaron S. [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
来源：
JOURNAL OF GENERAL INTERNAL MEDICINE | 2020年 / 35卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：S97 / S97
页数：1
相关论文
共 50 条
  • [21] PATTERN OF MARKET EXCLUSIVITY AND THE ENTRY OF ABBREVIATED NEW DRUG APPLICATIONS
    Wittayanukom, S.
    Dutcher, S.
    Zhao, L.
    Babiskin, A.
    VALUE IN HEALTH, 2017, 20 (05) : A60 - A60
  • [22] Market exclusivity after a prescription to nonprescription drug switch: Striking the right balance between innovation and competition
    Kraushaar, KJ
    FOOD AND DRUG LAW JOURNAL, 1999, 54 (02) : 243 - 244
  • [23] Pantoprazol-generic drug in the market
    不详
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2009, 47 (06): : 631 - 632
  • [24] European Union generic drug market
    Fauran, F
    MEDECINE ET MALADIES INFECTIEUSES, 1997, 27 : 545 - 547
  • [25] Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018
    Rome, Benjamin N.
    Lee, ChangWon C.
    Kesselheim, Aaron S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (02) : 367 - 371
  • [26] GENERIC DRUG MARKET ACCESS IN JAPAN
    Yoshida, E.
    Toumi, M.
    VALUE IN HEALTH, 2012, 15 (07) : A291 - A291
  • [27] Generic drug market: growing and merging
    不详
    LANCET ONCOLOGY, 2015, 16 (06): : 595 - 595
  • [28] Damages for loss of opportunity to enter generic market
    Mai Le Dinh
    JOURNAL OF INTELLECTUAL PROPERTY LAW & PRACTICE, 2009, 4 (03) : 149 - 151
  • [29] THE PRICING TRENDS OF ORAL PHARMACEUTICAL PRODUCTS ASSOCIATED WITH LOSS OF EXCLUSIVITY
    Bartolome, L.
    Varga, S.
    Ko, J. J.
    VALUE IN HEALTH, 2017, 20 (05) : A2 - A2
  • [30] Estimating the Causal Effect of Entry on Generic Drug Prices Using Hatch–Waxman Exclusivity
    Luke M. Olson
    Brett W. Wendling
    Review of Industrial Organization, 2018, 53 : 139 - 172
12345